A general aspect on soft-tissue sarcoma and c-kit expression in primitive neuroectodermal tumor and Ewing's sarcoma

Saudi Medical Journal

Volumn 26, Issue 8, 2005, Pages 1190-1196

  Kara, Ismail O ^a   Gonlusen, Gulfiliz ^a   Sahin, Berksoy ^a   Ergin, Melek ^a   Erdogan, Seyda ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PARAFFIN; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR;

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DISEASE COURSE; EWING SARCOMA; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; METASTASIS POTENTIAL; NEUROECTODERM TUMOR; PATHOGENESIS; PROTEIN EXPRESSION; SEX DIFFERENCE; SOFT TISSUE SARCOMA; TURKEY (REPUBLIC);

ADOLESCENT; ADULT; CHILD; FEMALE; HUMANS; MALE; NEUROECTODERMAL TUMORS, PRIMITIVE; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; RETROSPECTIVE STUDIES; SARCOMA, EWING'S;

EID: 24744460561     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8-31.
2. Lammie A, Drobnjak M, Gerald W, Saad A, Cote R, Cordon-Cardo C. Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem 1994; 42: 1417-1425.
3. Cambareri AC, Ashman LK, Cole SR, Lyons AB. A monoclonal antibody to a human mast cell/myeloid leukaemia-specific antigen binds to normal haemopoietic progenitor cells and inhibits colony formation in vitro. Leuk Res 1988; 12: 929-939.
4. Adachi S, Ebi Y, Nishikawa S, Hayashi S, Yamazaki M, Kasugai T, et al. Necessity of extracellular domain of W (c-kit) receptors for attachment of murine cultured mast cells to fibroblasts. Blood 1992; 79: 650-656.
5. Trojani M, Contesso G, Coindre JM, Rouesse J, Bui NB, de Mascarel A et al. Soft-tissue sarcomas of adults: study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 1984; 33: 37-42.
6. Gaynor JJ, Tan CC, Casper ES, Collin CF, Friedrich C, Shin M, et al. Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults. J Clin Oncol 1992; 10: 1317-1329.
7. Markhede G, Angervall L, Stener B. A multivariate analysis of the prognosis after surgical treatment of malignant soft-tissue tumors. Cancer 1982; 49: 1721-1733.
8. Sears HF, Hopson R, Inouye W, Rizzo T, Grotzinger PJ. Analysis of staging and management of patients with sarcoma: a ten-year experience. Ann Surg 1980; 191: 488-493.
9. Rydholm A, Berg NO, Gullberg B, Persson BM, Thomgren KG. Prognosis for softtissue sarcoma in the locomotor system. A retrospective population-based follow-up study of 237 patients. Acta Pathol Microbiol Immunol Scand [A] 1984; 92: 375-386.
10. Heise HW, Myers MH, Russell WO, Suit HD, Enzinger FM, Edmonson JH et al. Recurrence-free survival time for surgically treated soft tissue sarcoma patients. Multivariate analysis of five prognostic factors. Cancer 1986; 57: 172-177.
11. Rooser B, Attewell R, Berg NO, Rydholm A. Survival in soft tissue sarcoma. Prognostic variables identified by multivariate analysis. Acta Orthop Scand 1987; 58: 516-522.
12. Collin CF, Godbold J, Hajdu SI, Brennan MF. Localized extremity soft tissue sarcoma: an analysis of factors affecting survival. J Clin Oncol 1987; 5: 601-612.
13. Tsujimoto M, Aozasa K, Ueda T, Morimura Y, Komatsubara Y, Doi T. Multivariate analysis for histologic prognostic factors in soft tissue sarcomas. Cancer 1988; 62: 994-998.
14. Ueda T, Aozasa K, Tsujimoto M, Hamada H, Hayashi H, Ono K et al. Multivariate analysis for clinical prognostic factors in 163 patients. Cancer 1988; 62: 1444-1450.
15. Rooser B, Attewell R, Berg NO, Rydholm A. Prognostication in soft tissue sarcoma. A model with four risk factors. Cancer 1988; 61: 817-823.
16. Mandard AM, Petiot JF, Marnay J, Mandard JC, Chasle J, de Ranieri E, et al. Prognostic factors in soft tissue sarcomas. A multivariate analysis of 109 cases. Cancer 1989; 63: 1437-1451.
17. Bell RS, O'Sullivan B, Liu FF, Powell J, Langer F, Fornasier VL, et al. The surgical margin in soft-tissue sarcoma. J Bone Joint Surg (Am) 1989; 71: 370-375.
18. Emrich LJ, Ruka W, Driscoll DL, Karakousis CP. The effect of local recurrence on survival time in adult high-grade soft tissue sarcomas. J Clin Epidemiol 1989; 42: 105-110.
19. Stotter AT, Ahern RP, Fisher C, Mott AF, Followfield ME, Westbury G. The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival. Cancer 1990; 65: 1119-1129.
20. Alvegard TA, Berg NO, Baldetorp B, Ferno M, Killander D, Rantsam J et al. Cellular DNA content and prognosis of high-grade soft tissue sarcoma: the Scandinavian Sarcoma Group experience. J Clin Oncol 1990; 8: 538-547.
21. Pisters PWT, Leung DHY, Woodruff JM, Shi W, Brennan MF. Analysis of prognostic factors in 1041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996; 14: 1679-1689.
22. Coindre JM, Terrier P, Bui NB, Bonichan F, Collin F, Le Doussal V, et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol 1996; 14: 869-877.
23. Cance WG, Brennan MF, Dudas ME, Huang CM, Cordon-Cardo C. Altered expression of the retinoblastoma gene product in human sarcomas. N Engl J Med 1990; 323: 1457-1462.
24. Heslin MJ, Cordon-Cardo C, Lewis JJ, Woodruff JM, Brennan MF. Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma. Cancer 1998; 83: 490-497.
25. Karpeh MS, Brennan MF, Cance WG, Woodruff JM, Pollack D, Casper ES, et al. Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas. Br J Cancer 1995; 72: 986-991.
26. Kawai A, Woodruff JM, Healey JH, Brennan MF, Antonescu CR, Ladanyi M. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 1998; 338: 153-160.
27. Zoubek A, Dockhorn-Dworniczak B, Delattre O, Christiansen A, Niggli F, Gatterer-Menz I, et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 1996; 14: 1245-1251.
28. de Alava E, Kawai A, Healey JH, Fligman I, Meyers I, Huvos AG, et al. EWS-FLII fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 1998; 16: 1248-1255.
29. Anderson DM, Lyman SD, Baird A, Wignall JM, Eisemnan J, Rauch C, et al. Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. Cell 1990; 63: 235-243.
30. Avraham H, Scadden DT, Chi S, Broudy VC, Zsebo KM, Groopman JE. Interaction of human bone marrow fibroblasts with megakaryocytes: role of the c-kit ligand. Blood 1992; 80: 1679-1684.
31. Bacci G, Toni A, Avella M, Manfirini M, Sudanese A, Ciaroni D, et al. Long-term results in 144 localized Ewing's sarcoma patients treated with combined therapy. Cancer 1989; 63: 1477-1486.
32. Wang C, Curtis JE, Geissler EN, McCulloch EA, Minden MD. The expression of the proto-oncogene c-kit in the blast cells of acute myeloblastic leukemia. Leukemia 1989; 3: 699-702.
33. Williard WC, Collin CF, Casper ES, Hadju SI, Brennan MF. The changing role of amputation for soft tissue sarcoma of the extremity in adults. Surg Gynecol Obstet 1992; 175: 389-396.
34. Williard WC, Hajdu SI, Casper ES, Brennan MF. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg 1992; 215: 269-275.
35. Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996; 14: 859-868.
36. Yang JC, Chang AE, Baker AR, Sindelar MF, Danforth DN, Topolion SL, et al. A randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998; 16: 197-203.
37. Bramwell VHC, Rouesse J, Steward W, Santoro A, Schraffordt-Koops H, Buessa J et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1994; 12: 1137-1149.
38. van Glabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol 1999; 17: 150-157.
39. Amatruda JF, Tran K, Mantel M, Singer S, Demetri C. Diagnosis in oncology. A skin tumor. J Clin Oncol 1998; 16: 1997-1998.
40. Baldini EH, Demetri GD, Fletcher CD, Foran J, Marcus KC, Singer S. Adults with Ewing's sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome. Ann Surg 1999; 230: 79-86.
41. Turc-Carel C, Aurias A, Mugneret F, Lizard S, Sidaner I, Vollc C et al. Chromosomes in Ewing's sarcoma. An evaluation of 85 cases of remarkable consistency of t (11;22)(q24;ql2). Cancer Genet Cytogenet 1988; 32: 229-238.
42. Cohen PS, Chann JP, Lipkunskaya J, Seeger RC, Biedret JC, Seeger RJ. Expression of stem cell factor and c-kit in human neuroblastoma. the children's cancer group. Blood 1994; 84: 3465-3472.
43. Lerner NB, Nocka KH, Cole SR, Qiu FH, Strife A, Ashman LK, et al. Monoclonal antibody YB5.B8 identifies the human c-kit protein product. Blood 1991; 77: 1876-1883.
44. Natali PG, Nicotra MR, Sures I, Santoro E, Bigotti A, Ullrich A. Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Research 1992; 52: 6139-6143.
45. Simmons PJ, Aylett GW, Niutta S, To LB, Juttner CA, Ashman LK. c-kit is expressed by primitive human hematopoietic cells that give rise to to colony-forming cells in stroma-dependent or cytokine-supplemented culture. Exp Hematol 1994; 22: 157-165.
46. Ricotti E, Fagioli F, Garelli E, Linari C, Crescenzio H, Horenstein AC, et al. C-kit is expressed in soft tissue sarcoma of neuroectodermic origin and its ligand prevents apoptosis of neoplastic cells. Blood 1998; 91: 2397-2405.
47. Majumder S, Brown K, Qiu FH, Besmer P. c-kit protein, a transmembrane kinase: identification in tissues and characterization. Mol Cell Biol 1998; 8: 4896-4903.
48. Thiele CJ. Biology of pediatric peripheral neuroectodermal tumors. Cancer Metastasis Rev 1991; 10: 311-319.
49. Keshet E, Lyman SD, Williams DE, Anderson DM, Jenkins NA, Copeland NG et al. Embryonic RNA expression patterns of the c-kit receptor and its cognate ligand suggest multiple functional roles in mouse development. EMBO J 1991; 10: 2425-2435.
50. Timeus F, Crescenzio N, Valle P, Pistamiglio P, Piglione M, Garelli E et al. Stem cell factor suppresses apoptosis in neuroblastoma cell lines. Exp Hematol 1997; 25: 1253-1260.
51. Triche TJ, Askin FB. Neuroblastoma and the differential diagnosis of small round blue cell tumors. Hum Pathol 1983; 14: 569-595.
52. Broudy VC, Kovach NL, Bennett LG, Lin N, Jacobsen FW, Kidd PG. Human umbilical vein endothelial cells display high-affinity c-kit receptors and produce a soluble form of the c-kit receptor. Blood 1994; 83: 2145-2152.
53. Williams DE, Eisenman J, Baird A, Rauch C, Van NK, March CJ et al. Identification of a ligand for the c-kit proto-oncogene. Cell 1990; 63: 167.
54. Yarden Y, Kuang WS, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ et al. Human proto-oncogene c-kit, a new cell-surface-receptor tyrosine kinase for an unidentified ligand. EMBO J 1987; 6: 3341.